Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors from the central nervous system, conolidine modulates alternate molecular targets. A Science Advancements study found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR